Alumis (ALMS) EBIT Margin (2025 - 2026)
Alumis' (ALMS) quarterly EBIT Margin came in at 8956.38% in Q2 2026, down 368485.0% year-over-year from N/an in Q2 2025, and down 79.14% quarter-over-quarter from 4999.74% in Q4 2025.
Powered by 
Analysis
Alumis (ALMS) EBIT Margin (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported EBIT Margin for 2 consecutive years, with 8956.38% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBIT Margin fell 368485.0% year-over-year to 8956.38% in Q2 2026; TTM through Jun 2026 was 6021.04%, a N/A change from a year earlier, with the FY2025 full-year figure at 1886.92%, changed N/A from the prior year.
- EBIT Margin was 8956.38% for Q2 2026 at Alumis, down from 4999.74% in the prior quarter.
- Over five years, EBIT Margin peaked at 583.49% in Q1 2025 and troughed at 8956.38% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 30.15% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -562.07% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 32.54% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -25,380.93% |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | -8,956.38% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8,956.38% |
| Dec 31, 2025 | -4,999.74% |
| Sep 30, 2025 | -5,580.45% |
| Jun 30, 2025 | -5,271.53% |
| Mar 31, 2025 | -583.49% |